<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567552</url>
  </required_header>
  <id_info>
    <org_study_id>1412-BCN-087-AB</org_study_id>
    <secondary_id>2015-000290-12</secondary_id>
    <nct_id>NCT02567552</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone</brief_title>
  <official_title>Randomized Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone (Prolutex) 25 mg/Day Versus Intramuscular Progesterone (Prontogest) 50 mg/Day</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study the endometrial predecidualization by using subcutaneous progesterone 25 mg/day versus
      intramuscular progesterone 50 mg/day, to determine whether there are differences in the
      endometrial transformation and endometrial receptivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare predecidualization and endometrial receptivity as gene
      expression by using subcutaneous progesterone 25 mg/day versus intramuscular progesterone 50
      mg/day in healthy women of childbearing age. Both, the two drugs and the doses administered
      in this clinical trial, are routine clinical practice.

      A controlled ovarian stimulation will be previously performed and following routine clinical
      practice for 10-12 days at standard doses of subcutaneous FSH 150-225 IU/day, according to
      BMI and number of antral follicles. A GnRH antagonist shall be administered, being initiated
      according to donor's follicular growth from greater or equal14 mm diameter follicles. Final
      maturation shall be performed with a bolus of GnRH agonist when there exist at least 3
      follicles greater or equal17 mm diameter, and therefore performing follicular puncture 36
      hours after the bolus of agonist has been administered.

      If the donor meets the inclusion criteria, she will be informed of the study and, if she
      agrees, she will sign the informed consent. Randomization shall be performed in 2 arms; arm 1
      will be administered subcutaneous progesterone 25 mg/day (Prolutex; Angelini, Spain), and arm
      2, intramuscular progesterone 50 mg/day (Prontogest IBSA, Italy). In each arm 12 donors (ITT
      population) will be included.

      The randomization to a treatment group shall be performed the day the follicular puncture has
      been programmed. To that purpose, a randomized consecutive sampling will be used by means of
      assignment tables. The medication will be administered by a person not involved in the
      assessments and responsible for group assignment, data centralization and drug assignment.

      At day 5 (5 days after follicular puncture):endometrial thickness measurement by means of
      transvaginal ultrasound and perform endometrial biopsy and take two samples: 1 sample to
      Anatomical Pathology and 1 sample to Endometrial Receptivity Array (ERA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Masked samples for histological evaluation and assessment of gene expression</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Predecidual Transformation</measure>
    <time_frame>5 days</time_frame>
    <description>Histologic dating of the endometrium at day 5: early secretory phase, media secretory phase or late secretory phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decidualization of Stromal Cell</measure>
    <time_frame>5 days</time_frame>
    <description>Rate of transformation of endometrial stromal fibroblasts into specialized secretory decidual cells (three categories: less than 25%, between 26% and 50%, and over 50%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endometrial Maturation Using Noyes' Criteria</measure>
    <time_frame>5 days</time_frame>
    <description>Endometrial dating of luteal phase days according to the Noyes criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endometrial Gene Expression</measure>
    <time_frame>5 days</time_frame>
    <description>Gene expression profile of endometrial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endometrial Gene Expression Difference (Fold Change &gt;3)</measure>
    <time_frame>5 days</time_frame>
    <description>Genes with a significantly high gene expression difference (adj-p-value &lt; 0.05, Fold Change&gt;3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endometrial Thickness</measure>
    <time_frame>5 days</time_frame>
    <description>Endometrial thickness measurement by means of transvaginal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Estradiol Level</measure>
    <time_frame>day 0</time_frame>
    <description>Blood estradiol level on the day of follicular puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Progesterone Level</measure>
    <time_frame>day 0</time_frame>
    <description>Blood progesterone level on the day of follicular puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood LH Level</measure>
    <time_frame>day 0</time_frame>
    <description>Blood Luteinizing hormone level on the day of follicular puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Estradiol Level</measure>
    <time_frame>5 days</time_frame>
    <description>Blood estradiol level 5 days after progesterone treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Progesterone Level</measure>
    <time_frame>5 days</time_frame>
    <description>Blood progesterone level 5 days after progesterone treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood LH Level</measure>
    <time_frame>5 days</time_frame>
    <description>Blood Luteinizing hormone level 5 days after progesterone treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Side Effects During the Study</measure>
    <time_frame>5 days</time_frame>
    <description>Number of Participants with side effects during the study&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Reproductive Techniques, Assisted</condition>
  <arm_group>
    <arm_group_label>Prolutex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prontogest</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous progesterone</intervention_name>
    <description>subcutaneous progesterone 25 mg/day</description>
    <arm_group_label>Prolutex</arm_group_label>
    <other_name>Prolutex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular progesterone</intervention_name>
    <description>intramuscular progesterone 50 mg/day</description>
    <arm_group_label>Prontogest</arm_group_label>
    <other_name>Prontogest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged between 18 and 34 years

          -  BMI between 18 and 28 kg/m2

          -  Endometrial thickness &gt; 7 mm the day of progesterone treatment initiation (day of
             follicular puncture)

          -  Follicular maturation with a single bolus of GnRH agonist

          -  Egg donors who undergo a cycle of ovarian stimulation in the IVI Barcelona Centre

          -  Egg donors selected in accordance with the requirements of Law 14/2006 of 26 May 2006
             on Assisted Human Reproduction Techniques

          -  Informed consent has been signed and dated

        Exclusion Criteria:

          -  Known allergy to progesterone formulations or their excipients

          -  Known allergy to estrogens

          -  Known thrombophilias

          -  Alcohol, drug or psychotropic medication dependence

          -  Concurrent participation in another study

          -  Concomitant medication that may interfere with the study medication and ovarian
             stimulation

          -  Failure to comply with the requirements for egg donors in accordance with Law 14/2006
             of 26 May 2006 on Assisted Human Reproduction Techniques
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustín B Boluda</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <results_first_submitted>February 23, 2017</results_first_submitted>
  <results_first_submitted_qc>August 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2018</results_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial receptivity</keyword>
  <keyword>endometrial predecidualization</keyword>
  <keyword>endometrial genomics</keyword>
  <keyword>endometrial receptivity array</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prolutex</title>
          <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Prontogest</title>
          <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11">dropout by pain in the puncture site</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prolutex</title>
          <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Prontogest</title>
          <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.92" spread="5.32"/>
                    <measurement group_id="B2" value="25.58" spread="2.39"/>
                    <measurement group_id="B3" value="26.25" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.76" spread="2.88"/>
                    <measurement group_id="B2" value="23.12" spread="2.79"/>
                    <measurement group_id="B3" value="22.44" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.75" spread="5.10"/>
                    <measurement group_id="B2" value="162.08" spread="3.50"/>
                    <measurement group_id="B3" value="164.42" spread="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.00" spread="10.05"/>
                    <measurement group_id="B2" value="61.00" spread="8.55"/>
                    <measurement group_id="B3" value="61.00" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Progesterone Level</title>
          <description>Blood progesterone level in Day -2</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.31" spread="0.85"/>
                    <measurement group_id="B2" value="1.44" spread="0.77"/>
                    <measurement group_id="B3" value="1.37" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Estradiol Level</title>
          <description>Blood Estradiol Level in day -2</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2020.35" spread="998.36"/>
                    <measurement group_id="B2" value="2464.33" spread="1144.19"/>
                    <measurement group_id="B3" value="2262.52" spread="1078.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood LH level</title>
          <description>Blood LH level in day -2</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.25" spread="0.45"/>
                    <measurement group_id="B2" value="1.24" spread="0.91"/>
                    <measurement group_id="B3" value="1.25" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Endometrial Thickness</title>
          <description>Endometrial Thickness in day 0</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.88" spread="1.98"/>
                    <measurement group_id="B2" value="9.58" spread="1.61"/>
                    <measurement group_id="B3" value="9.23" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Predecidual Transformation</title>
        <description>Histologic dating of the endometrium at day 5: early secretory phase, media secretory phase or late secretory phase</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Predecidual Transformation</title>
          <description>Histologic dating of the endometrium at day 5: early secretory phase, media secretory phase or late secretory phase</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>early secretory phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>media secretory phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>late secretory phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3395</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Decidualization of Stromal Cell</title>
        <description>Rate of transformation of endometrial stromal fibroblasts into specialized secretory decidual cells (three categories: less than 25%, between 26% and 50%, and over 50%)</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Decidualization of Stromal Cell</title>
          <description>Rate of transformation of endometrial stromal fibroblasts into specialized secretory decidual cells (three categories: less than 25%, between 26% and 50%, and over 50%)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;25% of stromal cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25-50% of stromal cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 50% of stromal cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1523</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endometrial Maturation Using Noyes' Criteria</title>
        <description>Endometrial dating of luteal phase days according to the Noyes criteria</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Maturation Using Noyes' Criteria</title>
          <description>Endometrial dating of luteal phase days according to the Noyes criteria</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.08" spread="2.23"/>
                    <measurement group_id="O2" value="7.64" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison between groups</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1189</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endometrial Gene Expression</title>
        <description>Gene expression profile of endometrial</description>
        <time_frame>5 days</time_frame>
        <population>We assessed the gene expression of 238 endometrial genes to detect differences in gene expression between treatments.
This analysis could not be performed in 1 patient of the prolutex group because of the poor quality of the sample collected</population>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Gene Expression</title>
          <description>Gene expression profile of endometrial</description>
          <population>We assessed the gene expression of 238 endometrial genes to detect differences in gene expression between treatments.
This analysis could not be performed in 1 patient of the prolutex group because of the poor quality of the sample collected</population>
          <units>Endometrial genes</units>
          <param>Number</param>
          <units_analyzed>Endometrial genes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Endometrial genes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>differential expressed genes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>the same trend of gene expression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endometrial Thickness</title>
        <description>Endometrial thickness measurement by means of transvaginal ultrasound.</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Thickness</title>
          <description>Endometrial thickness measurement by means of transvaginal ultrasound.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.46" spread="2.66"/>
                    <measurement group_id="O2" value="9.61" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2042</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Estradiol Level</title>
        <description>Blood estradiol level on the day of follicular puncture</description>
        <time_frame>day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Estradiol Level</title>
          <description>Blood estradiol level on the day of follicular puncture</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1384.06" spread="1122.80"/>
                    <measurement group_id="O2" value="1208.58" spread="502.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6262</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Progesterone Level</title>
        <description>Blood progesterone level on the day of follicular puncture</description>
        <time_frame>day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Progesterone Level</title>
          <description>Blood progesterone level on the day of follicular puncture</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.40" spread="6.63"/>
                    <measurement group_id="O2" value="10.92" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2301</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood LH Level</title>
        <description>Blood Luteinizing hormone level on the day of follicular puncture</description>
        <time_frame>day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Blood LH Level</title>
          <description>Blood Luteinizing hormone level on the day of follicular puncture</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.89"/>
                    <measurement group_id="O2" value="2.75" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5118</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Estradiol Level</title>
        <description>Blood estradiol level 5 days after progesterone treatment</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Estradiol Level</title>
          <description>Blood estradiol level 5 days after progesterone treatment</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.88" spread="150.65"/>
                    <measurement group_id="O2" value="246.45" spread="106.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8371</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Progesterone Level</title>
        <description>Blood progesterone level 5 days after progesterone treatment</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Progesterone Level</title>
          <description>Blood progesterone level 5 days after progesterone treatment</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="1.00"/>
                    <measurement group_id="O2" value="11.04" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood LH Level</title>
        <description>Blood Luteinizing hormone level 5 days after progesterone treatment</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Blood LH Level</title>
          <description>Blood Luteinizing hormone level 5 days after progesterone treatment</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.60"/>
                    <measurement group_id="O2" value="2.92" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3107</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Side Effects During the Study</title>
        <description>Number of Participants with side effects during the study&quot;</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Side Effects During the Study</title>
          <description>Number of Participants with side effects during the study&quot;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endometrial Gene Expression Difference (Fold Change &gt;3)</title>
        <description>Genes with a significantly high gene expression difference (adj-p-value &lt; 0.05, Fold Change&gt;3)</description>
        <time_frame>5 days</time_frame>
        <population>We assessed the expressed genes with a significantly high gene expression difference between treatments (adj-p-value &lt; 0.05, Fold Change&gt;3) This analysis could not be performed in 1 patient of the prolutex group because of the poor quality of the sample collected</population>
        <group_list>
          <group group_id="O1">
            <title>Prolutex</title>
            <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Prontogest</title>
            <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Gene Expression Difference (Fold Change &gt;3)</title>
          <description>Genes with a significantly high gene expression difference (adj-p-value &lt; 0.05, Fold Change&gt;3)</description>
          <population>We assessed the expressed genes with a significantly high gene expression difference between treatments (adj-p-value &lt; 0.05, Fold Change&gt;3) This analysis could not be performed in 1 patient of the prolutex group because of the poor quality of the sample collected</population>
          <units>Endometrial genes</units>
          <param>Number</param>
          <units_analyzed>Endometrial genes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Endometrial genes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>expressed genes with fold change &gt; 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>expressed genes without or with fold change &lt; 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prolutex</title>
          <description>Subcutaneous progesterone
Subcutaneous progesterone: subcutaneous progesterone 25 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Prontogest</title>
          <description>Intramuscular progesterone
Intramuscular progesterone: intramuscular progesterone 50 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in injection site</sub_title>
                <description>Pain in injection site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Discomfort in injection site</sub_title>
                <description>Discomfort in injection site</description>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast inflammation</sub_title>
                <description>Breast inflammation</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Evelin Lara Molina</name_or_title>
      <organization>IVI Barcelona</organization>
      <phone>+34 93 531 63 00 ext 27503</phone>
      <email>Evelin.Lara@ivi.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

